Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Slides:



Advertisements
Similar presentations
Figure 1 Disruption of phosphate homeostasis in chronic kidney disease (CKD) Figure 1 | Disruption of phosphate homeostasis in chronic kidney disease (CKD).
Advertisements

Nat. Rev. Nephrol. doi: /nrneph
Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.
Figure 4 Interplay between acute kidney injury (AKI),
Figure 6 Effects of adiponectin on podocyte function
Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.
Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.
Figure 6 Differences in glycaemic control with the study drug
Figure 4 Interactions between adipose, the microbiome and kidney
Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Mechanisms of kidney injury in the setting of obesity
Figure 2 Physiological changes in the renal system in pregnancy
Figure 1 Types of coronary artery calcification
Figure 2 Proinflammatory mechanisms in CKD
Figure 1 Circadian changes in energy metabolism and immune responses in CKD Figure 1 | Circadian changes in energy metabolism and immune responses in CKD.
Figure 1 Role of the kidney in glucose homeostasis
Figure 3 The fat–intestine–kidney axis
Nat. Rev. Nephrol. doi: /nrneph
Figure 4 BMI and mortality in patients with heart failure
Nat. Rev. Nephrol. doi: /nrneph
Nat. Rev. Cardiol. doi: /nrcardio
Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.
Figure 7 The efficacy of phosphate-binder therapy
Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)
Figure 5 Risk factor control in the intensive treatment group
Figure 2 The network of chronic diseases and their mutual influences
Figure 2 Three distinct mechanisms of activation of
Figure 1 The burden of chronic kidney disease (CKD)
Figure 3 The 'leaky gut' hypothesis
Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.
Nat. Rev. Nephrol. doi: /nrneph
Figure 2 Podocyte dysfunction is a common feature of renal injury
Figure 2 Mechanisms of the gut–autonomic
Figure 1 Acute kidney injury and chronic kidney disease
Figure 2 The continuum of acute kidney injury (AKI),
Figure 4 Model of changes in the serum levels
Nat. Rev. Nephrol. doi: /nrneph
Figure 5 Consequences of CKD on lipid metabolism
Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.
Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Specificity of the various epidermal growth factor (EGF)
Figure 2 Organ crosstalk in the pathophysiology
Nat. Rev. Nephrol. doi: /nrneph
Nat. Rev. Nephrol. doi: /nrneph
cardiovascular and renal systems
Nat. Rev. Nephrol. doi: /nrneph
Figure 3 Challenges for big data applications in cardiovascular care
Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Distinct features of adipocytes
Nat. Rev. Nephrol. doi: /nrneph
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Nephrol. doi: /nrneph
Figure 3 Serum phosphate level is associated with
Figure 1 CD36 structure and post-translational modifications
Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Mechanistic classification of lncRNAs
Nat. Rev. Nephrol. doi: /nrneph
Figure 2 Biologics that target CD4+ T helper (TH)-cell subsets
Figure 1 Patient, facility, health-care system and industry factors
Figure 2 Impaired mitochondrial capacity and function in heart failure
Figure 4 The relationship between the time-dependent changes in the expression of immunoglobulin, mast cell, acute kidney injury (AKI), and fibrillar collagen.
Nat. Rev. Cardiol. doi: /nrcardio
Figure 4 Intracellular distribution and
Figure 2 Lifelong influences on the gut microbiome from
Figure 1 Worldwide distribution of disease burden attributable to environmental risks in 2012 Figure 1 | Worldwide distribution of disease burden attributable.
Targeting Immunity in End-Stage Renal Disease
Nat. Rev. Nephrol. doi: /nrneph
Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. Incidence of contrast-induced nephropathy in patients.
Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Relationships between genetic variants, quantitative traits and diseases Figure 1 | Relationships between genetic variants, quantitative traits.
Presentation transcript:

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in CKD. Aswell as causing the retention of uraemic toxins (including toxins generated in the intestinal system), chronic kidney disease (CKD) alters the integrity of the intestinal barrier, which leads to translocation of intestinal microbiota into the blood, systemic inflammation, increased absorption of uraemic toxins from the intestine and cardiovascular disease. Uraemic toxins are strong proinflammatory stimuli. Cardiovascular disease also contributes to alter the intestinal barrier via venous intestinal congestion secondary to heart failure. Zoccali, C. et al. (2017) The systemic nature of CKD Nat. Rev. Nephrol. doi:10.1038/nrneph.2017.52